Upstream Bio’s (UPB) “Sell (D-)” Rating Reiterated at Weiss Ratings

Weiss Ratings reissued their sell (d-) rating on shares of Upstream Bio (NASDAQ:UPB) in a report published on Friday,Weiss Ratings reports.

Separately, Truist Financial began coverage on Upstream Bio in a report on Tuesday, October 14th. They set a “buy” rating and a $47.00 price objective on the stock. Five investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $53.33.

Upstream Bio Stock Performance

NASDAQ UPB opened at $21.86 on Friday. The stock’s 50-day moving average price is $18.58 and its two-hundred day moving average price is $13.66. Upstream Bio has a 1 year low of $5.14 and a 1 year high of $29.46.

Upstream Bio (NASDAQ:UPB) last posted its quarterly earnings data on Wednesday, August 6th. The company reported ($0.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.61) by ($0.13). The company had revenue of $0.94 million for the quarter, compared to analyst estimates of $0.32 million. Upstream Bio had a negative return on equity of 35.90% and a negative net margin of 3,836.58%. As a group, equities analysts expect that Upstream Bio will post -4.3 earnings per share for the current fiscal year.

Institutional Trading of Upstream Bio

Hedge funds have recently made changes to their positions in the stock. Nuveen LLC purchased a new stake in shares of Upstream Bio in the first quarter worth approximately $138,000. Parkman Healthcare Partners LLC acquired a new position in Upstream Bio in the first quarter worth approximately $1,429,000. New York State Common Retirement Fund acquired a new position in Upstream Bio in the first quarter worth approximately $29,000. XTX Topco Ltd acquired a new position in Upstream Bio in the first quarter worth approximately $78,000. Finally, ADAR1 Capital Management LLC acquired a new position in Upstream Bio in the first quarter worth approximately $92,000.

About Upstream Bio

Upstream Bio, Inc, a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.